| Literature DB >> 32419804 |
Soukayna Hriouech1, Ahmed A Akhmouch1, Aouatef Mzabi1, Hanane Chefchaou1, Mariam Tanghort1, Bouchra Oumokhtar2, Najat Chami1, Adnane Remmal1.
Abstract
The aim of this research paper is to test the antistaphylococcal effect of 1,8-cineole, amoxicillin/clavulanic acid (AMC), and gentamicin, either separately or in combination against three Staphylococcus aureus strains isolated from patients suffering from osteomyelitis. This activity was tested in vitro by using the microdilution method and the checkerboard assay. The efficacy of these three antibacterial agents was then tested in vivo by using an experimental model of methicillin-resistant S. aureus osteomyelitis in rabbits. This efficacy was assessed after four days of treatment by counting the number of bacteria in the bone marrow. The obtained results in vitro showed that the combination of the AMC with gentamicin did not induce a synergistic effect, whereas the combination of the two antibiotics with 1,8-cineole did. This effect is stronger when AMC is combined with 1,8-cineole as a total synergistic effect was obtained on the three strains used (FIC ≤ 0.5). In vivo, a significant reduction was noted in the number of colonies in the bone marrow when rabbits were treated with AMC associated with either 1,8-cineole or gentamicin compared to rabbits treated with AMC, gentamicin, or 1,8-cineole alone. These results demonstrated that 1,8-cineole showed a synergistic effect in combination with both AMC and gentamicin, which offer possibilities for reducing antibiotic usage. Also, the AMC associated with 1,8-cineole could be used to treat MRSA osteomyelitis.Entities:
Year: 2020 PMID: 32419804 PMCID: PMC7206863 DOI: 10.1155/2020/4271017
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Resistance profile of the strains used.
| Bacterial strains | Antibiotic resistance profile |
|---|---|
| MRSA | Penicillin, cefoxitin, gentamycin, erythromycin, norfloxacin, cotrimoxazole, |
| MSSA1 | Penicillin and tetracycline |
| MSSA2 | Susceptible |
MIC values.
|
| MIC | ||
|---|---|---|---|
| AMC ( | Gentamicin ( | 1,8-Cineole(mg/mL) | |
| MRSA | 1 | 2 | 32 |
| MSSA1 | 0.5 | 0.5 | 16 |
| MSSA2 | 0.25 | 1 | 32 |
Effect of the combination of AMC with Gentamicin.
|
| AMC (A) | Gentamicin (B) | FICI | Type of interaction | ||||
|---|---|---|---|---|---|---|---|---|
| MIC alone | MIC combined | FIC (A) | MIC alone | MIC combined | FIC (B) | |||
| MRSA | 1 | 0.5 | 0.5 | 2 | 1 | 0.5 | 1 | Additive |
| MSSA1 | 0.5 | 0.5 | 1 | 0.5 | 0.25 | 0.5 | 1.5 | No interaction |
| MSSA2 | 0.25 | 0.125 | 0.5 | 1 | 0.5 | 0.5 | 1 | Additive |
Effect of the combination of AMC with 1,8-cineole.
|
| AMC (A) | 1,8-Cineole (B) | FICI | Type of interaction | ||||
|---|---|---|---|---|---|---|---|---|
| MIC alone | MIC combined | FIC (A) | MIC alone | MIC combined | FIC (B) | |||
| MRSA | 1 | 0.25 | 0.25 | 32 | 4 | 0.125 | 0.375 | Synergy |
| MSSA1 | 0.5 | 0.125 | 0.25 | 16 | 4 | 0.25 | 0.5 | Synergy |
| MSSA2 | 0.25 | 0.062 | 0.25 | 32 | 2 | 0.062 | 0.312 | Synergy |
Effect of the combination of gentamicin with 1,8-cineole.
|
| Gentamicin (A) | 1,8-cineole (B) | FICI | Type of interaction | ||||
|---|---|---|---|---|---|---|---|---|
| MIC alone | MIC combined | FIC (A) | MIC alone | MIC combined | FIC (B) | |||
| MRSA | 2 | 0.5 | 0.25 | 32 | 8 | 0.25 | 0.5 | Synergy |
| MSSA1 | 0.5 | 0.25 | 0.5 | 16 | 4 | 0.25 | 0.75 | Partial synergy |
| MSSA2 | 1 | 0.5 | 0.5 | 32 | 8 | 0.25 | 0.75 | Partial synergy |
Figure 1Changes in body temperature of rabbits. The values followed by different letters are significantly different from each other at p < 0.05.
Evolution of body weight. The values followed by different letters are significantly different from the values of the positive control group at p < 0.05.
| Groups | |||||||
|---|---|---|---|---|---|---|---|
| Time (day) | Positive control | AMC | Gentamicin | 1,8-cineole | AMC + gentamicin | AMC + 1,8-cineole | Negative control |
| Day 0 | 1473 ± 157a | 1450.33 ± 11a | 1450.33 ± 118.44a | 1443.66 ± 109.56a | 1531.33 ± 179a | 1735.33 ± 149a | 1513 ± 128a |
| Day 3 | 1419 ± 16a | 1401.67 ± 113a | 1401.66 ± 119.56a | 1395 ± 115a | 1476 ± 189a | 1687 ± 142a | 1596.33 ± 132a |
| Day 7 | 1458.67 ± 114a | 1497.33 ± 113a | 1497.33 ± 119.78a | 1487.33 ± 113a | 1594 ± 182a | 1807 ± 148a | 1729.67 ± 140a |
| Day 14 | 1568.33 ± 135a | 1660.67 ± 140a | 1660.66 ± 147.56a | 1650.66 ± 140a | 1777 ± 147a | 2002 ± 145b | 1973 ± 148b |
Figure 2Evolution of the bacterial load in bone marrow in log10 CFU/g. The values followed by different letters are significantly different from each other at p < 0.05.
Difference in bacterial load in the bone marrow between day 3 and day 7. The values followed by different letters are significantly different from each other at p < 0.05.
| Groups | Mean ± SD log10 CFU/g (day 3–day 7) |
|---|---|
| Positive control ( | (0,68 ± 0,48) b |
| AMC ( | (−2,04 ± 0,47) d |
| Gentamicin ( | (−2,06 ± 0.49) d |
| 1,8-cineole ( | (−0.56 ± 0.06) c |
| AMC + Gentamicin ( | (−3,40 ± 0,4) e |
| AMC+1,8-cineole ( | (−3,43 ± 0,41) e |
| Negative control ( | (0 ± 0) a |